Verification of Genetic Differences and Immune Cell Infiltration Subtypes in the Neuroblastoma Tumour Microenvironment During Immunotherapy

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Specialties General Surgery
Oncology

Date 2022 Jun 1

PMID 35643506

Authors

Bo Qian

Jing Sun

Pengcheng Zuo

Min Da

Xuming Mo

Yongjun Fang

Affiliations

Soon will be listed here.

Abstract

Background: Improved understanding of the tumour microenvironment (TME) has enabled remarkable advancements in research on cancer progression in the past few years. It is crucial to understand the nature and function of the TME because precise treatment strategies, including immunotherapy, for managing specific cancers have received widespread attention. The immune infiltrative profiles of neuroblastoma (NB) have not yet been completely illustrated. The purpose of this research was to analyse tumour immune cell infiltration (ICI) in the microenvironment of NB.

Methods: We applied the CIBERSORT and ESTIMATE algorithms to evaluate the ICI status of 438 NB samples. Three ICI models were selected, and ICI scores were acquired. Subgroups with high ICI scores determined based on the presence of immune activation signalling pathways had better overall survival.

Results: Genes involved in the immunosuppressive heparan sulphate glycosaminoglycan biosynthesis signalling pathway were markedly enriched in the low ICI score subgroup. It was inferred that patients with high ICI NB subtypes were more likely to respond to immunotherapy and have a better prognosis than those of patients with low ICI NB subtypes.

Conclusion: Notably, our ICI data not only provide a new clinical and theoretical basis for mining NB prognostic markers related to the microenvironment but also offer new ideas for the development of NB precision immunotherapy methods.

Citing Articles

Biological Insight and Recent Advancement in the Treatment of Neuroblastoma.

Rivera Z, Escutia C, Madonna M, Gupta K Int J Mol Sci. 2023; 24(10).

PMID: 37239815 PMC: 10218416. DOI: 10.3390/ijms24108470.

References

Ramani V, Purushothaman A, Stewart M, Thompson C, Vlodavsky I, Au J . The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J. 2013; 280(10):2294-306. PMC: 3651779. DOI: 10.1111/febs.12168. View

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

Mehrabadi A, Roozbahani F, Ranjbar R, Farzanehpour M, Shahriary A, Dorostkar R . Overview of the pre-clinical and clinical studies about the use of CAR-T cell therapy of cancer combined with oncolytic viruses. World J Surg Oncol. 2022; 20(1):16. PMC: 8756705. DOI: 10.1186/s12957-021-02486-x. View

Dondero A, Pastorino F, Della Chiesa M, Corrias M, Morandi F, Pistoia V . PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance. Oncoimmunology. 2016; 5(1):e1064578. PMC: 4760291. DOI: 10.1080/2162402X.2015.1064578. View

Perdicchio M, Ilarregui J, Verstege M, Cornelissen L, Schetters S, Engels S . Sialic acid-modified antigens impose tolerance via inhibition of T-cell proliferation and de novo induction of regulatory T cells. Proc Natl Acad Sci U S A. 2016; 113(12):3329-34. PMC: 4812702. DOI: 10.1073/pnas.1507706113. View

Boboila S, Lopez G, Yu J, Banerjee D, Kadenhe-Chiweshe A, Connolly E . Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma. Oncogene. 2018; 37(40):5451-5465. PMC: 6172192. DOI: 10.1038/s41388-018-0326-9. View

Eissler N, Mao Y, Brodin D, Reutersward P, Andersson Svahn H, Johnsen J . Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade. Oncoimmunology. 2017; 5(12):e1232222. PMC: 5214950. DOI: 10.1080/2162402X.2016.1232222. View

Borriello L, Nakata R, Sheard M, Fernandez G, Sposto R, Malvar J . Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells. Cancer Res. 2017; 77(18):5142-5157. PMC: 5600847. DOI: 10.1158/0008-5472.CAN-16-2586. View

Chen D, Mellman I . Elements of cancer immunity and the cancer-immune set point. Nature. 2017; 541(7637):321-330. DOI: 10.1038/nature21349. View

10.

Jiang Y, Zhang Q, Hu Y, Li T, Yu J, Zhao L . ImmunoScore Signature: A Prognostic and Predictive Tool in Gastric Cancer. Ann Surg. 2016; 267(3):504-513. DOI: 10.1097/SLA.0000000000002116. View

11.

Qu H, Zheng L, Pu J, Mei H, Xiang X, Zhao X . miRNA-558 promotes tumorigenesis and aggressiveness of neuroblastoma cells through activating the transcription of heparanase. Hum Mol Genet. 2015; 24(9):2539-51. DOI: 10.1093/hmg/ddv018. View

12.

Zhang C, Zheng J, Lin Z, Lv H, Ye Z, Chen Y . Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma. Aging (Albany NY). 2020; 12(4):3486-3501. PMC: 7066877. DOI: 10.18632/aging.102824. View

13.

Zhang X, Shi M, Chen T, Zhang B . Characterization of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma to Aid Immunotherapy. Mol Ther Nucleic Acids. 2020; 22:298-309. PMC: 7522342. DOI: 10.1016/j.omtn.2020.08.030. View

14.

Voeller J, Erbe A, Slowinski J, Rasmussen K, Carlson P, Hoefges A . Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition. J Immunother Cancer. 2019; 7(1):344. PMC: 6898936. DOI: 10.1186/s40425-019-0823-6. View

15.

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman D . IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017; 127(8):2930-2940. PMC: 5531419. DOI: 10.1172/JCI91190. View

16.

Pelizzo G, Veschi V, Mantelli M, Croce S, Di Benedetto V, DAngelo P . Microenvironment in neuroblastoma: isolation and characterization of tumor-derived mesenchymal stromal cells. BMC Cancer. 2018; 18(1):1176. PMC: 6260687. DOI: 10.1186/s12885-018-5082-2. View

17.

He Y, Jiang Z, Chen C, Wang X . Classification of triple-negative breast cancers based on Immunogenomic profiling. J Exp Clin Cancer Res. 2018; 37(1):327. PMC: 6310928. DOI: 10.1186/s13046-018-1002-1. View

18.

Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov J . Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011; 27(12):1739-40. PMC: 3106198. DOI: 10.1093/bioinformatics/btr260. View

19.

Chen Y, Wang Y, Lv J, Li Y, Chua M, Le Q . Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy. Ann Oncol. 2018; 30(1):68-75. DOI: 10.1093/annonc/mdy470. View

20.

Callari M, Cappelletti V, DAiuto F, Musella V, Lembo A, Petel F . Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer. Clin Cancer Res. 2015; 22(2):337-45. DOI: 10.1158/1078-0432.CCR-15-0757. View